Lipids, lifestyle and prevention

Name: Lipids, lifestyle and prevention
Start: 2022-09-13T12:00:00+00:00
End: 2022-09-14T10:00:00+00:00

Manoir de Gressy, France

13 Sep 2022 - 14 Sep 2022

Add to calendar 2022-09-13T14:00 2022-09-14T12:00 Europe/Paris Lipids, lifestyle and prevention

CRT Onsite

A two-half-day workshop chaired by Prof. François Mach, Prof. Frank Visseren, Dr. Nilo Cater (Pfizer), Dr. Jarkko Soronen (Daiichi-Sankyo) and Dr. Nejoua Salhi (Amgen).

Programme

Day 1 | 13 September 2022 | 14:00–18:00

14:00–14:10 - Welcome, introduction and workshop objectives by Chairpersons
14:10–15:00 - SESSION 1: Residual risk with lipid-lowering therapy: what is the scope of the problem?
- 14:10–14:20 - What are the key insights from registries/real-world studies? by Prof. Kausik Ray (London)
- 14:20–14:30 - How can imaging be utilized to characterize residual risk? by Dr. Victoria Delgado (Leiden)
- 14:30–15:00 - Discussion
15:00–16:00 - SESSION 2: Addressing residual risk beyond statin therapy: what is the current landscape for add-on/combination therapy?
- 15:00–15:10 - Strategies targeting PCSK9 (MoAb, siRNA) by Prof. Wouter Jukema (Leiden)
- 15:10–15:20 - Strategies targeting ACL by Prof. Ulrich Laufs (Leipzig)
- 15:20–15:30 - How IPE can potentially address residual risk in patients on statins/other therapies by Prof. Jose-Luis Zamorano (Madrid)
- 15:30–16:00 - Discussion
16:30–17:00 - SESSION 3: What is the role of heart healthy diets?
- 16:30–16:40 - Mediterranean diet: lessons from PREDIMED by Prof. Emilio Ros (Barcelona)
- 16:40–16:50 - Role of phytosterols and fiber by Prof. Jogchum Plat (Maastricht)
- 16:50–17:00 - Discussion
17:00–17:30 - LECTURE: What are the insights into targeting inflammation to reduce residual risk with lipid-lowering therapies? by Prof. Peter Libby (Boston, via Zoom)
17:30–18:00 - Panel discussion
17:30 - END OF DAY 1

Day 2 | 14 September 2022 | 09:00–12:30

09:30–09:45 - Summary of Day 1 by Chairpersons
09:45–10:30 - SESSION 5: Patient perspective on lipid-lowering therapy
- 09:45–10:30 - Patient perspective by Dr. Akos Gesztes (Hungary)
10:30–11:00 - SESSION 6: Addressing residual risk beyond statin therapy: How is the evolving landscape for strategies targeting non-LDL Cholesterol (Lp(a), ApoCIII, ANGPTL3)?
- 10:30–10:50 - Overview by Prof. Lale Tokgozoglu (Ankara)
- 10:50–11:05 - Focus on anti-Lp(a) as target of therapy by Prof. Chris Packard (Glasgow)
- 11:05–11:30 - Panel Discussion
11:30–11:45 - Wrap-up, summary and next steps for a publication by Chairpersons
End of the workshop